drugset
drugset / Trial / NCT04095793

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

NCT04095793 ↗

Phase 3 Terminated 110 enrolled Theravance Biopharma
NaSingle-groupOpen-labelTreatment

Summary

A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.

Timeline

Start
2019-09-19
Primary completion
2021-11-12
Completion
2021-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ampreloxetine Small molecule — Oral

Indications

orthostatic hypotension